Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

YOKE vs AARD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AARD Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 5–3 Matrix Metrics)

AARD Overall Winner 6-Pillar Tally: YOKE 0 – 4 AARD (2 Tie) Matrix Metrics: YOKE 3 – 5 AARD

As of Nov 16, 2026, Aardvark Therapeutics, Inc. (AARD) is the stronger overall head-to-head candidate over YOKE Core ETF (YOKE) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). YOKE carries a Unified Composite Score of 50.9/100 (HOLD) at $30.57 (N/M Forward P/E, N/A operating margin), whereas AARD carries 49.1/100 (HOLD) at $1.26 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While YOKE currently prints a higher short-term Unified Composite Score (50.9/100 HOLD vs. AARD 49.1/100 HOLD), AARD captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: YOKE is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 42.3); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About YOKE vs AARD
YOKE NASDAQ
YOKE Core ETF
Institutional Equity
$30.57
-1.64% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.98β · 19% Vol
Unified Composite Score
50.9 / 100 HOLD
Tech 49.0 Fund 55.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.0%) with fading momentum, RSI 42
RSI-14: 42.3 · SMA20: $31.05 · SMA50: $31.12
AARD NASDAQ Head-to-Head Winner
Aardvark Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.26
-5.26% 1D
Market Cap $29.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.10β · 288% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 53.0 Fund 63.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.9%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $1.74 · SMA50: $3.68

6-Pillar Scorecard Institutional Category Breakdown (YOKE 0 – 4 AARD)

Columns: Metric · YOKE · AARD
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale AARD
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $29.1M
3. Profitability & Quality AARD
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -66.0%
4. Balance Sheet & Cash Flow AARD
Cash Generation (TTM) N/A -$69M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $73M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AARD
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 147.3% (26th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: YOKE (3) vs AARD (5)
Institutional Metric YOKE AARD Criterion Row Edge
Market Capitalization
Scale
N/A $29.1M Larger Scale AARD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth AARD
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin AARD
Net Profit Margin
Profitability
N/A 0.0% Higher Margin AARD
Return on Equity (ROE)
Capital Efficiency
N/A -66.0% Higher ROE AARD
52-Week Range Position
Momentum
64% ($26–$33) 2% ($1–$17) Stronger Trend YOKE
Beta / 30D Volatility
Risk Regime
0.98β · 19% Vol 4.10β · 288% Vol Lower Realized Risk YOKE
Unified Institutional Score
Composite Signal
50.9 / 100 (HOLD) 49.1 / 100 (HOLD) Higher Composite YOKE
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$69M ($73M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon YOKE +64.12 pp
YOKE: -2.55% · AARD: -66.67%
3M Horizon YOKE +74.21 pp
YOKE: -5.29% · AARD: -79.5%
6M Horizon YOKE +70.52 pp
YOKE: -0.58% · AARD: -71.1%
1Y Horizon YOKE +102.47 pp
YOKE: +14.07% · AARD: -88.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on YOKE vs AARD. Trailing 12-month operating profitability (YOKE N/A vs AARD 0.0%) and valuation multiples (YOKE N/M vs AARD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

YOKE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
AARD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-66.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
YOKE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact YOKE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AARD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 147.3%
IV Percentile 26th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AARD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
YOKE Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AARD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $29.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ YOKE vs AARD Key Questions & Quantitative Answers

As of Nov 16, 2026, Aardvark Therapeutics, Inc. (AARD) is the stronger overall head-to-head candidate over YOKE Core ETF (YOKE) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). YOKE carries a Unified Composite Score of 50.9/100 (HOLD) at $30.57 (N/M Forward P/E, N/A operating margin), whereas AARD carries 49.1/100 (HOLD) at $1.26 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While YOKE currently prints a higher short-term Unified Composite Score (50.9/100 HOLD vs. AARD 49.1/100 HOLD), AARD captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: YOKE is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 42.3); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AARD leads the Growth & Scale pillar: YOKE posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with AARD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, YOKE generates N/A in USD-normalized revenue versus N/A for AARD. In operating R&D and SG&A reinvestment, YOKE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AARD.

YOKE and AARD trade at balanced relative valuation multiples. YOKE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AARD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against YOKE (N/A ROE) versus AARD (-66.0% ROE) capital efficiency.

In options market volatility and institutional positioning, YOKE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 19% Vol realized risk). By comparison, AARD carries 147.3% implied volatility (26th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.10β · 288% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.